1-甲基-反-1,2-环丙烷二羧酸二甲酯 | 702-92-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-甲基-反-1,2-环丙烷二羧酸二甲酯
• 英文名称: 1-Methyl-r-1,t-2-cyclopropandicarbonsaeure-dimethylester
• 英文别名: (+/-)-1-methyl-cyclopropane-dicarboxylic acid-(1r.2t)-dimethyl ester；(+/-)-1-Methyl-cyclopropan-dicarbonsaeure-(1r.2t)-dimethylester；1-Methyl-cyclopropan-1r,2t-dicarbonsaeure-dimethylester；1-Methyl-cyclopropan-trans-1,2-dicarbonsaeure-dimethylester；dimethyl (1R,2R)-1-methylcyclopropane-1,2-dicarboxylate
• CAS: 702-92-1
• 化学式: C₈H₁₂O₄
• 分子量: 172.181
• InChiKey: NDRULFBEMISCLM-YLWLKBPMSA-N

物化性质

• 沸点：
  97 °C (18 mmHg)
• 密度：
  1.2104 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 安全说明：
  S24/25

SDS

Name:	Dimethyl 1-Methyl-Trans-1 2-Cyclopropanedicarboxylate 99+% Material Safety Data Sheet
Synonym:	None known
CAS:	702-92-1

Section 1 - Chemical Product MSDS Name:Dimethyl 1-Methyl-Trans-1 2-Cyclopropanedicarboxylate 99+% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
702-92-1	Dimethyl 1-Methyl-Trans-1,2-Cyclopropa	99+	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use water spray to keep fire-exposed containers cool. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Containers may explode when heated.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Cool containers with flooding quantities of water until well after fire is out. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Avoid runoff into storm sewers and ditches which lead to waterways.
Clean up spills immediately, observing precautions in the Protective Equipment section. Absorb spill using an absorbent, non-combustible material such as earth, sand, or vermiculite. Do not use combustible materials such as sawdust. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 702-92-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear, colorless
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 97 deg C @ 18.00mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H12O4
Molecular Weight: 172.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, ignition sources, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 702-92-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Dimethyl 1-Methyl-Trans-1,2-Cyclopropanedicarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 702-92-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 702-92-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 702-92-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-反-1,2-环丙烷二羧酸二甲酯 在 盐酸 作用下， 生成 反式-1-甲基-1,2-环丙烷二羧酸
  参考文献：
  名称：

  Synthesis and mode of action of 1-substituted trans-cyclopropane 1,2-dicarboxylic acids: inhibitors of the methylaspartase reaction

  摘要：

  我们采用简捷高效的方法合成了一系列 1-取代环丙烷 1,2 二羧酸，发现它们是 3-甲基天冬氨酸酶的良好至强效抑制剂；经晶体学测定，最强效抑制剂 (1S,2S)-1- 甲基环丙烷 1,2 二羧酸的绝对立体化学结构和作用模式与它作为该酶催化的中心底物脱氨反应的过渡态类似物是一致的。

  DOI：

  10.1039/cc9960000675
• 作为产物：
  描述：

  柠康酸二甲酯 在 重氮甲烷 、 乙醚 作用下， 生成 1-甲基-反-1,2-环丙烷二羧酸二甲酯
  参考文献：
  名称：

  v.Auwers; Cauer, Justus Liebigs Annalen der Chemie, 1929, vol. 470, p. 298

  摘要：

  DOI：

文献信息

• 1,5-bis(trimethylsiloxy)-1, 5-dimethoxy-1, 4-pentadienes
  作者：I.H.M. Wallace、T.H. Chan

  DOI：10.1016/s0040-4020(01)88582-3

  日期：1983.1

  1, 5-Bis(trimethylsiloxy)-1, 5-dimethoxy-1, 4-pentadienes (7) can be prepared in good yield by silylation of the dianions of dimethyl glutarates (8). On treatment with titanium tetrachloride, 7 cyclise stereoselectively to dimethyl trans-cyclopropane-1, 2-dicarboxylates 10. Reaction of 7 with acetic anhydrode and titanium tetrachloride gives substituted cyclobutanes 22b–d.

  通过将戊二酸二甲酯（8）的二价硅烷基化，可以高收率制备1，5-双（三甲基甲硅烷氧基）-1、5-二甲氧基-1、4-戊二烯（7）。在用四氯化钛处理时，7环化立体选择性地二甲基反式-环丙烷-1，2-二羧酸盐10。7与乙酸酐和四氯化钛反应生成取代的环丁烷22b–d。
• <b>Nuclear Magnetic Resonance Spectroscopy. Cyclopropane Derivatives</b>
  作者：Dinshaw J. Patel、M. E. H. Howden、John D. Roberts

  DOI：10.1021/ja00903a036

  日期：1963.10

  constants have been determined from the analysis of proton nuclear magnetic resonance spectra for a series of cyclopropane derivatives. The geminal and vicinal cyclopropyl couplings have opposite signs. Additional ^(13)C-H coupling constants have been obtained for cyclopropanes which support the conclusion that the hybridization of the carbon-hydrogen bonding orbitals in cyclopropanes is close to sp. The chemical

  通过对一系列环丙烷衍生物的质子核磁共振谱的分析，已经确定了化学位移和耦合常数。孪生和邻位环丙基偶联具有相反的符号。已经获得了环丙烷的额外 ^(13)CH 偶联常数，这支持了环丙烷中碳氢键轨道的杂化接近 sp 的结论。几种环丙烷烃的化学位移似乎与环流效应一致。
• Thermal isomerization of cis- and trans-dimethyl epoxymethylsuccinate to dimethyl α-oxoglutarate
  作者：Paul Dowd、Kilmo Kang

  DOI：10.1039/c39740000258

  日期：——

  rearrangement of the methyl substituted epoxides, cis- and trans-dimethyl epoxymethylsuccinate, to the straight-chain ketone, dimethyl α-oxo-glutarate, is described together with the patially analogous rearrangements of the cis- and trans-dimethyl 1-methylcyclopropane-1,2-dicarboxylates into dimethyl α-methyleneglutarate and cis- and trans-dimethyl 1,2-dimethylaziridine-2,3-dicarboxylates into methyl

  甲基取代的环氧化物，不寻常的重排顺-和反式-二甲基epoxymethylsuccinate，以直链酮，二甲基α氧代-戊二酸，是连同的patially类似的重排中描述的顺式-和反式-二甲基-1-甲基环丙烷-1,2-二羧酸酯成α-亚甲基戊二酸二甲酯和顺-和反-二甲基1,2-二甲基氮丙啶-2,3-二羧酸酯成1-甲氧基羰基（甲基）丙烯酸甲酯。
• Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20050107389A1

  公开（公告）日：2005-05-19

  The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代酰胺衍生物，其表现出对多巴胺D3受体的选择性结合。在另一个方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备上述化合物的过程，以及将这些化合物作为多巴胺D3受体成像剂的方法。
• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。